Evidence for impaired CARD15 signalling in Crohn's disease without disease linked variants

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Seidelin, Jakob Benedict ^a   Broom, Oliver Jay ^a   Olsen, Jørgen ^b   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MURAMYL DIPEPTIDE; CYTOKINE; INTERLEUKIN 1BETA; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; NOD2 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENOTYPE; HUMAN; INNATE IMMUNITY; MONOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; SIGNAL TRANSDUCTION; EXON; GENETIC VARIABILITY; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALIA;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; CROHN DISEASE; CYTOKINES; EXONS; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MAP KINASE SIGNALING SYSTEM; MONOCYTES; NF-KAPPA B; NOD2 SIGNALING ADAPTOR PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 70649085135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007794     Document Type: Article

References (31)

1. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, et al. (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367: 668-678.
2. Kanneganti TD, Lamkanfi M, Nunez G (2007) Intracellular NOD-like receptors in host defense and disease. Immunity 27: 549-559.
3. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
5. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, et al. (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278: 8869-8872.
6. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, et al. (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194-199.
7. Kim JY, Omori E, Matsumoto K, Nunez G, Ninomiya-Tsuji J (2008) TAK1 is a central mediator of NOD2 signaling in epidermal cells. J Biol Chem 283: 137-144.
8. Hsu YM, Zhang Y, You Y, Wang D, Li H, et al. (2007) The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 8: 198-205.
9. Martinon F, Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117: 561-574.
10. Martinon F, Agostini L, Meylan E, Tschopp J (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14: 1929-1934.
11. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, et al. (2007) Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 25: 713-724.
12. Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, et al. (2008) A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A 105: 7803-7808.
13. Singer II, Scott S, Chin J, Bayne EK, Limjuco G, et al. (1995) The interleukin-1 beta-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy. J Exp Med 182: 1447-1459.
14. van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, et al. (2005) Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365: 1794-1796.
15. Kramer M, Netea MG, de Jong DJ, Kullberg BJ, Adema GJ (2006) Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol 79: 860-866.
16. Netea MG, Ferwerda G, de Jong DJ, Werts C, Boneca IG, et al. (2005) The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. J Biol Chem 280: 35859-35867.
17. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, et al. (2005) Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734-738.
18. Peeters H, Bogaert S, Laukens D, Rottiers P, De KF, et al. (2007) CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease. Int J Immunogenet 34: 181-191.
19. Netea MG, Ferwerda G, de Jong DJ, Jansen T, Jacobs L, et al. (2005) Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174: 6518-6523.
20. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, et al. (2007) The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 13: 24-32.
21. Seidelin JB, Nielsen OH (2006) Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. APMIS 114: 508-517.
22. Milman N, Nielsen OH, Hviid TV, Fenger K (2007) CARD15 single nucleotide polymorphisms 8, 12 and 13 are not increased in ethnic Danes with sarcoidosis. Respiration 74: 76-79.
23. Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, et al. (2007) Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology 133: 1487-1498.
24. Korzenik JR (2007) Is Crohn's disease due to defective immunity? Gut 56: 2-5.
25. Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, et al. (2004) NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 34: 2052-2059.
26. Wolfert MA, Murray TF, Boons GJ, Moore JN (2002) The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan. J Biol Chem 277: 39179-39186.
27. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168: 5342-5351.
28. Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, et al. (2005) Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 174: 7096-7103.
29. Hedl M, Li J, Cho JH, Abraham C (2007) Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A 104: 19440-19445.
30. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, et al. (2008) Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 118: 545-559.
31. McAlindon ME, Hawkey CJ, Mahida YR (1998) Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42: 214-219.